A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Trial Profile

A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Feb 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bendamustine
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 19 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 07 Dec 2015 Results published at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, as per Seattle Genetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top